{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:10:46Z","timestamp":1794564646685,"version":"4.9.1"},"reference-count":54,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:p>The separation of benign from malignant mesothelial proliferations is an important clinical but often a difficult morphologic problem. Over the last roughly 10 years a variety of new markers that aid in this separation have been published and some older recommended markers reconsidered. Unlike previous, and largely unusable, empiric immunohistochemical (IHC) stains, these new markers, some using IHC and some using fluourescent in situ hybridization (FISH), are largely based on documented genomic abnormalities in malignant mesotheliomas. However, no marker works in all situations; rather, markers need to be chosen by the morphology of the process in question (epithelial vs. spindled) and the body cavity of interest (pleural vs. peritoneal). It is also important to be familiar with the exact pattern, for example nuclear versus cytoplasmic loss, that indicates a positive test. Furthermore, no single marker is 100% sensitive even with the optimal morphology\/location, so that combinations of markers are essential. This review covers the various new markers in the literature, highlights their advantages and limitations, and suggests morphology\/site specific combinations that can produce sensitivities in the 80% to 90% (and perhaps higher) range. At present only BRCA-1 related protein-1 and methylthioadenosine phosphorylase IHC, and <jats:italic toggle=\"yes\">cyclin-dependent kinase inhibitor 2A<\/jats:italic> (p16) FISH have sufficient publications and reproducibility of results to be considered as established markers. 5-Hydroxymethyl cytosine, enhancer of zeste homolog 2, cyclin D1, and programmed death-ligand 1 IHC, and <jats:italic toggle=\"yes\">NF2<\/jats:italic> FISH are all potentially useful but need further study. The newly described entity of malignant mesothelioma in situ sits at the interface of benign and malignant mesothelial process; criteria for this diagnosis are reviewed.<\/jats:p>","DOI":"10.1097\/pas.0000000000001565","type":"journal-article","created":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T16:08:24Z","timestamp":1598026104000},"page":"e100-e112","source":"Crossref","is-referenced-by-count":54,"title":["The Separation of Benign and Malignant Mesothelial Proliferations"],"prefix":"10.1097","volume":"44","author":[{"given":"Andrew","family":"Churg","sequence":"first","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital"},{"name":"Department of Pathology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia R.","family":"Naso","sequence":"additional","affiliation":[{"name":"Department of Pathology, Vancouver General Hospital"},{"name":"Department of Pathology, University of British Columbia, Vancouver, BC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"R1-20230922","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.5858\/arpa.2012-0112-RA","article-title":"The separation of benign and malignant mesothelial proliferations: update 2012","volume":"136","author":"Churg","year":"2012","journal-title":"Arch Pathol Lab Med"},{"key":"R2-20230922","doi-asserted-by":"crossref","first-page":"318","DOI":"10.5858\/arpa.2015-0240-SA","article-title":"New markers for separating benign from malignant mesothelial proliferations: are we there yet?","volume":"140","author":"Churg","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R3-20230922","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","article-title":"Pan-cancer analysis of whole genomes","volume":"578","year":"2020","journal-title":"Nature"},{"key":"R4-20230922","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/nature22798","article-title":"BAP1 regulates IP3R3-mediated Ca(2+) flux to mitochondria suppressing cell transformation","volume":"546","author":"Bononi","year":"2017","journal-title":"Nature"},{"key":"R5-20230922","doi-asserted-by":"crossref","first-page":"68863","DOI":"10.18632\/oncotarget.20317","article-title":"Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis","volume":"8","author":"Wang","year":"2017","journal-title":"Oncotarget"},{"key":"R6-20230922","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1038\/ng.912","article-title":"Germline BAP1 mutations predispose to malignant mesothelioma","volume":"43","author":"Testa","year":"2011","journal-title":"Nat Genet"},{"key":"R7-20230922","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.lungcan.2016.12.017","article-title":"Immunohistochemical detection of MTAP and BAP1 protein loss for mesothelioma diagnosis: comparison with 9p21 FISH and BAP1 immunohistochemistry","volume":"104","author":"Hida","year":"2017","journal-title":"Lung Cancer"},{"key":"R8-20230922","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/modpathol.2015.65","article-title":"BAP1 (BRCA1-associated protein 1) is a highly specific marker for differentiating mesothelioma from reactive mesothelial proliferations","volume":"28","author":"Cigognetti","year":"2015","journal-title":"Mod Pathol"},{"key":"R9-20230922","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1097\/PAS.0000000000000394","article-title":"BAP1 immunohistochemistry and p16 FISH to separate benign from malignant mesothelial proliferations","volume":"39","author":"Sheffield","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"R10-20230922","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1097\/PAS.0000000000000976","article-title":"Loss of BAP1 expression in atypical mesothelial proliferations helps to predict malignant mesothelioma","volume":"42","author":"Pillappa","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R11-20230922","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.lungcan.2018.09.019","article-title":"A combination of MTAP and BAP1 immunohistochemistry is effective for distinguishing sarcomatoid mesothelioma from fibrous pleuritis","volume":"125","author":"Kinoshita","year":"2018","journal-title":"Lung Cancer"},{"key":"R12-20230922","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/j.humpath.2015.06.024","article-title":"BAP1 facilitates diagnostic objectivity, classification, and prognostication in malignant pleural mesothelioma","volume":"46","author":"McGregor","year":"2015","journal-title":"Hum Pathol"},{"key":"R13-20230922","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/PAS.0000000000000616","article-title":"BAP1 immunohistochemistry and p16 FISH in the diagnosis of sarcomatous and desmoplastic mesotheliomas","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R14-20230922","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jtho.2019.08.2506","article-title":"EURACAN\/IASLC proposals for updating the histologic classification of pleural mesothelioma: towards a more multidisciplinary approach","volume":"15","author":"Nicholson","year":"2020","journal-title":"J Thorac Oncol"},{"key":"R15-20230922","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/modpathol.2015.121","article-title":"The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma","volume":"29","author":"Singhi","year":"2016","journal-title":"Mod Pathol"},{"key":"R16-20230922","doi-asserted-by":"crossref","first-page":"236","DOI":"10.5858\/arpa.2017-0092-OA","article-title":"Immunohistochemistry in peritoneal mesothelioma: a single-center experience of 244 cases","volume":"142","author":"Tandon","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R17-20230922","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1038\/modpathol.2015.87","article-title":"Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology","volume":"28","author":"Andrici","year":"2015","journal-title":"Mod Pathol"},{"key":"R18-20230922","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1093\/jnci\/djy171","article-title":"Comprehensive study of the clinical phenotype of germline BAP1 variant-carrying families worldwide","volume":"110","author":"Walpole","year":"2018","journal-title":"J Natl Cancer Inst"},{"issue":"suppl 1","key":"R19-20230922","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.21037\/tlcr.2019.11.24","article-title":"BAP1: role in carcinogenesis and clinical implications","volume":"9","author":"Kobrinski","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"R20-20230922","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.humpath.2015.12.012","article-title":"Loss of BAP1 expression is very rare in peritoneal and gynecologic serous adenocarcinomas and can be useful in the differential diagnosis with abdominal mesothelioma","volume":"51","author":"Andrici","year":"2016","journal-title":"Hum Pathol"},{"key":"R21-20230922","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.humpath.2016.10.005","article-title":"Loss of BRCA1-associated protein 1 (BAP1) expression is rare in non-small cell lung cancer","volume":"60","author":"Owen","year":"2017","journal-title":"Hum Pathol"},{"key":"R22-20230922","doi-asserted-by":"crossref","first-page":"59314","DOI":"10.18632\/oncotarget.10653","article-title":"Positive nuclear BAP1 immunostaining helps differentiate non-small cell lung carcinomas from malignant mesothelioma","volume":"7","author":"Carbone","year":"2016","journal-title":"Oncotarget"},{"key":"R23-20230922","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1136\/jmedgenet-2011-100156","article-title":"Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers","volume":"48","author":"Abdel-Rahman","year":"2011","journal-title":"J Med Genet"},{"key":"R24-20230922","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1749-6632.1999.tb09414.x","article-title":"BAP1, a candidate tumor suppressor protein that interacts with BRCA1","volume":"886","author":"Jensen","year":"1999","journal-title":"Ann N Y Acad Sci"},{"key":"R25-20230922","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12881-019-0909-5","article-title":"Copy number variation is highly correlated with differential gene expression: a pan-cancer study","volume":"20","author":"Shao","year":"2019","journal-title":"BMC Med Genet"},{"key":"R26-20230922","doi-asserted-by":"crossref","first-page":"6963","DOI":"10.1158\/1078-0432.CCR-09-1511","article-title":"Homozygous deletion of MTAP gene as a poor prognosticator in gastrointestinal stromal tumors","volume":"15","author":"Huang","year":"2009","journal-title":"Clin Cancer Res"},{"key":"R27-20230922","first-page":"2108","article-title":"Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas","volume":"9","author":"Illei","year":"2003","journal-title":"Clin Cancer Res"},{"key":"R28-20230922","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/modpathol.2009.186","article-title":"CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival","volume":"23","author":"Krasinskas","year":"2010","journal-title":"Mod Pathol"},{"key":"R29-20230922","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.5858\/arpa.2018-0273-OA","article-title":"Utility of methylthioadenosine phosphorylase compared with BAP1 immunohistochemistry, and CDKN2A and NF2 fluorescence in situ hybridization in separating reactive mesothelial proliferations from epithelioid malignant mesotheliomas","volume":"142","author":"Berg","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"R30-20230922","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1038\/s41379-019-0310-0","article-title":"MTAP immunohistochemistry is an accurate and reproducible surrogate for CDKN2A fluorescence in situ hybridization in diagnosis of malignant pleural mesothelioma","volume":"33","author":"Chapel","year":"2020","journal-title":"Mod Pathol"},{"key":"R31-20230922","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/his.13872","article-title":"Cytoplasmic MTAP expression loss detected by immunohistochemistry correlates with 9p21 homozygous deletion detected by FISH in pleural effusion cytology of mesothelioma","volume":"75","author":"Hamasaki","year":"2019","journal-title":"Histopathology"},{"key":"R32-20230922","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1378\/chest.09-1951","article-title":"Fluorescence in situ hybridization in the definitive diagnosis of malignant mesothelioma in effusion cytology","volume":"138","author":"Savic","year":"2010","journal-title":"Chest"},{"key":"R33-20230922","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1097\/PAS.0000000000000529","article-title":"Utility of BAP1 immunohistochemistry and p16 (CDKN2A) FISH in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"40","author":"Hwang","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"R34-20230922","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/cncy.21928","article-title":"A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma","volume":"126","author":"Kinoshita","year":"2018","journal-title":"Cancer Cytopathol"},{"key":"R35-20230922","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/cncr.10923","article-title":"The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions","volume":"99","author":"Illei","year":"2003","journal-title":"Cancer"},{"key":"R36-20230922","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1111\/cas.12769","article-title":"Deletion status of p16 in effusion smear preparation correlates with that of underlying malignant pleural mesothelioma tissue","volume":"106","author":"Hida","year":"2015","journal-title":"Cancer Sci"},{"key":"R37-20230922","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/cncy.22221","article-title":"Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens","volume":"128","author":"Berg","year":"2020","journal-title":"Cancer Cytopathol"},{"key":"R38-20230922","first-page":"311","article-title":"Hippo pathway\u2014brief overview of its relevance in cancer","volume":"68","author":"Zygulska","year":"2017","journal-title":"J Physiol Pharmacol"},{"key":"R39-20230922","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s12967-019-1869-4","article-title":"Analysis of the role of the Hippo pathway in cancer","volume":"17","author":"Han","year":"2019","journal-title":"J Transl Med"},{"key":"R40-20230922","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1158\/2159-8290.CD-18-0804","article-title":"Integrative molecular characterization of malignant pleural mesothelioma","volume":"8","author":"Hmeljak","year":"2018","journal-title":"Cancer Discov"},{"key":"R41-20230922","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s41379-019-0309-6","article-title":"Hemizygous loss of NF2 detected by fluorescence in situ hybridization is useful for the diagnosis of malignant pleural mesothelioma","volume":"33","author":"Kinoshita","year":"2020","journal-title":"Mod Pathol"},{"key":"R42-20230922","doi-asserted-by":"crossref","first-page":"391","DOI":"10.5858\/arpa.2015-0508-LE","article-title":"Immunohistochemistry for NF2, LATS1\/2, and YAP\/TAZ fails to separate benign from malignant mesothelial proliferations","volume":"140","author":"Sheffield","year":"2016","journal-title":"Arch Pathol Lab Med"},{"key":"R43-20230922","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/s41379-019-0411-9","article-title":"Cyclin D1 immunohistochemical staining to separate benign from malignant mesothelial proliferations","volume":"33","author":"Pors","year":"2020","journal-title":"Mod Pathol"},{"key":"R44-20230922","doi-asserted-by":"crossref","first-page":"85624","DOI":"10.18632\/oncotarget.12928","article-title":"Epigenetic regulation of cancer biology and anti-tumor immunity by EZH2","volume":"7","author":"Christofides","year":"2016","journal-title":"Oncotarget"},{"key":"R45-20230922","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1111\/his.13123","article-title":"Diagnostic utility of BAP1 and EZH2 expression in malignant mesothelioma","volume":"70","author":"Shinozaki-Ushiku","year":"2017","journal-title":"Histopathology"},{"key":"R46-20230922","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.lungcan.2019.02.004","article-title":"Highly expressed EZH2 in combination with BAP1 and MTAP loss, as detected by immunohistochemistry, is useful for differentiating malignant pleural mesothelioma from reactive mesothelial hyperplasia","volume":"130","author":"Yoshimura","year":"2019","journal-title":"Lung Cancer"},{"key":"R47-20230922","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.cancergen.2015.02.009","article-title":"5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy","volume":"208","author":"Vasanthakumar","year":"2015","journal-title":"Cancer Genet"},{"key":"R48-20230922","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41379-018-0159-7","article-title":"Immunohistochemical evaluation of nuclear 5-hydroxymethylcytosine (5-HMC) accurately distinguishes malignant pleural mesothelioma from benign mesothelial proliferations","volume":"32","author":"Chapel","year":"2019","journal-title":"Mod Pathol"},{"key":"R49-20230922","doi-asserted-by":"crossref","first-page":"185","DOI":"10.5858\/arpa.2019-0370-OA","article-title":"Use of programmed death ligand-1 (PD-L1) staining to separate sarcomatoid malignant mesotheliomas from benign mesothelial reactions","volume":"144","author":"Derakhshan","year":"2020","journal-title":"Arch Pathol Lab Med"},{"key":"R50-20230922","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/s41379-019-0328-3","article-title":"Expression of V-set immunoregulatory receptor in malignant mesothelioma","volume":"33","author":"Chung","year":"2020","journal-title":"Mod Pathol"},{"key":"R51-20230922","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.blre.2018.04.005","article-title":"Blocking \u201cdon\u2019t eat me\u201d signal of CD47-SIRPalpha in hematological malignancies, an in-depth review","volume":"32","author":"Russ","year":"2018","journal-title":"Blood Rev"},{"key":"R52-20230922","doi-asserted-by":"crossref","first-page":"e1373235","DOI":"10.1080\/2162402X.2017.1373235","article-title":"The \u201cdon\u2019t eat me\u201d signal CD47 is a novel diagnostic biomarker and potential therapeutic target for diffuse malignant mesothelioma","volume":"7","author":"Schurch","year":"2017","journal-title":"Oncoimmunology"},{"key":"R53-20230922","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1038\/s41379-019-0347-0","article-title":"Malignant mesothelioma in situ: morphologic features and clinical outcome","volume":"33","author":"Churg","year":"2020","journal-title":"Mod Pathol"},{"key":"R54-20230922","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00428-019-02674-x","article-title":"Malignant mesothelioma in situ diagnosed by methylthioadenosine phosphorylase loss and homozygous deletion of CDKN2A: a case report","volume":"476","author":"Minami","year":"2020","journal-title":"Virchows Arch"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001565","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T22:56:05Z","timestamp":1695423365000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001565"}},"subtitle":["New Markers and How to Use Them"],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":54,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001565","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8,20]]}}}